Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Agomelatine, a novel antidepressant exerting its effects through melatonergic and serotonergic systems, implicated to be effective against pain including neuropathic pain but without any knowledge of mechanism of action. To explore the possible role of agomelatine on nociceptive transmission at the peripheral level, the effects of agomelatine on intracellular calcium ([Ca ] ) signaling in peripheral neurons were investigated in cultured rat dorsal root ganglion (DRG) neurons. Using the fura-2-based calcium imaging technique, the effects of agomelatine on [Ca ] and roles of the second messenger-mediated pathways were assessed. Agomelatine caused [Ca ] signaling in a dose-dependent manner when tested at 10 and 100 μM concentration. Luzindole, a selective melatonin receptor antagonist, almost completely blocked the agomelatine-induced calcium signals. The agomelatine-induced calcium transients were also nearly abolished following pretreatment with the 100 ng/ml pertussis toxin, a Gi/o protein inhibitor. The stimulatory effects of agomelatine on [Ca ] transients were significantly reduced by applications of phospholipase C (PLC) and protein kinase C (PKC) blockers, 10 μM U73122, and 10 μM chelerythrine chloride, respectively. The obtained results of agomelatine-induced [Ca ] signals indicates that peripheral mechanisms are involved in analgesic effects of agomelatine. These mechanisms seems to involve G-protein-coupled receptor activation and PLC and PKC mediated mechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.27748DOI Listing

Publication Analysis

Top Keywords

effects agomelatine
16
agomelatine
8
protein kinase
8
[ca signaling
8
agomelatine [ca
8
agomelatine-induced calcium
8
calcium
5
effects
5
[ca
5
agomelatine modulates
4

Similar Publications

Background: A wide range of drugs is used to alleviate insomnia symptoms in individuals with severe mental illness (SMI), including licensed drugs and sedating drugs prescribed off-label. Yet, no review has gathered the evidence on illness-specific or transdiagnostic outcomes of pharmacological interventions for insomnia. We aimed to perform a systematic review and meta-analysis of randomised controlled trials (RCTs) studying the efficacy and acceptability of pharmacological interventions for insomnia among individuals with SMI, defined as schizophrenia, bipolar disorder (BD) or major depressive disorder (MDD).

View Article and Find Full Text PDF

Alzheimer's disease (AD) has become a serious health problem. Agomelatine (Ago) is a neuroprotective antidepressant. This study aimed to assess how Ago influences behavioral outcomes in AD-like rat model.

View Article and Find Full Text PDF

The aim of this study is to investigate the potential synergistic effects of agomelatine(AGM) and 2600 MHz radiofrequency(RF) field exposure on inflammation induced by chronic lipopolysaccharide(LPS) administration in rats. A total of 49 female Wistar albino rats were randomly divided into 7 groups( = 7 per group): Control, Sham, LPS, LPS+AGM,LPS+RF,AGM+RF, and LPS+AGM+RF. Animals in the RF groups were exposed to a 2600 MHz field (1 h/day for 15 days).

View Article and Find Full Text PDF

Agomelatine and Empagliflozin Synergistically Protect Against Diabetic Cardiomyopathy via Nrf2/HO-1 Signaling.

Eur J Pharmacol

August 2025

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. Electronic address:

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes with limited therapeutic options. This study investigated the potential synergistic cardioprotective effects of combining agomelatine (AGM), a melatonergic agonist, with empagliflozin (EMPA), an SGLT2 inhibitor, in a mouse model of DCM. Diabetes was induced in mice using streptozotocin.

View Article and Find Full Text PDF

Background: Anti-anxiety medications' side effects and dependency risks necessitate thorough consideration of their efficacy and acceptability when making treatment decisions.

Methods: A systematic review and Network Meta-Analysis (NMA) was conducted using three databases from 1980 to 2020, focusing on adults diagnosed with generalized anxiety disorder (GAD) or any relevant diagnostic classification of anxiety disorder or those for whom Hamilton Anxiety (HAM-A) data is available, and including any comparator (placebo and/or active comparator treatments). The primary outcomes were efficacy (mean difference in change from baseline in HAM-A total score) and acceptability (study discontinuations for any cause).

View Article and Find Full Text PDF